Hyseq Pharmaceuticals, Inc. to Be Featured at BIO 2002 Business Forum
SUNNYVALE, Calif., June 7 /PRNewswire-FirstCall/ -- Hyseq Pharmaceuticals, Inc. (Nasdaq: HYSQ - News), today announced that Ted W. Love, M.D., president and CEO, will be presenting at the BIO 2002 Business Forum in Toronto, Ontario, on Wednesday, June 12, 2002 at 3:15 p.m. EDT.
Dr. Love will provide a brief corporate overview and discuss the company's near-term milestones, including the upcoming initiation of Phase I trials for alfimeprase, Hyseq's lead product candidate to treat peripheral arterial occlusion.
A live audio and visual webcast of the presentation will be available online at events01.activate.net or via Hyseq's Web site at www.hyseq.com.
About Hyseq
Hyseq Pharmaceuticals, Inc. is engaged in research and development of novel biopharmaceutical products from its collection of proprietary genes discovered using its high-throughput screening-by-hybridization platform. Hyseq's screening-by-hybridization platform provided a significant advantage in discovering novel, rarely-expressed genes, and assembly of one of the most important proprietary databases of full-length human gene sequences. Hyseq is expanding and accelerating its research activities to further elucidate the role of novel genes in its proprietary database. Hyseq's database includes genes which encode a number of therapeutically important classes of molecules including chemokines, growth factors, stem cell factors, interferons, integrins, proteases, hormones, receptors, and other potential protein therapeutics or drug targets.
Information about Hyseq Pharmaceuticals, Inc. is available at www.hyseq.com or by phoning 408-524-8100.
SOURCE: Hyseq Pharmaceuticals, Inc. |
